Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Royal Prima TbkISX:PRIM 65 Days Sales Outstanding is 89.71 as of Jun. 2026, which is 0% above its 10-year median of 89.70. GuruFocus rates ISX:PRIM with a GF Score™ of 65/100 and a GF Value™ of Rp78.36 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 664 Healthcare Providers & Services companies, PT Royal Prima Tbk ranks worse than 80.27% on this metric.
The historical rank and industry rank for PT Royal Prima Tbk's Days Sales Outstanding or its related term are showing as below:
ISX:PRIM'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 35.96 Med: 89.7 Max: 111.81
Current: 91.38
During the past 12 years, PT Royal Prima Tbk's highest Days Sales Outstanding was 111.81. The lowest was 35.96. And the median was 89.70.
ISX:PRIM's Days Sales Outstanding is ranked worse than 80.27% of 664
companies
in the Healthcare Providers & Services industry
Industry Median: 45.78
vs ISX:PRIM: 91.38
PT Royal Prima Tbk's Days Sales Outstanding
declined
from Jun. 2025 (91.53) to Jun. 2026 (89.71).
PT Royal Prima Tbk (ISX:PRIM) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
PT Royal Prima Tbk Days Sales Outstanding Related Terms
PT Royal Prima Tbk Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for PT Royal Prima Tbk's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:PRIM vs HCA, THC, EHC: Days Sales Outstanding Comparison
For the Medical Care Facilities subindustry, PT Royal Prima Tbk's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Royal Prima Tbk Days Sales Outstanding vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PT Royal Prima Tbk's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where PT Royal Prima Tbk's Days Sales Outstanding falls into.
PT Royal Prima Tbk Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Royal Prima Tbk (ISX:PRIM) has a Days Sales Outstanding of 89.71 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on PT Royal Prima Tbk and its competitors. This is near median its historical median of 89.70. Over the past decade, PT Royal Prima Tbk's Days Sales Outstanding has ranged from 35.96 to 111.81. According to the industry distribution chart, PT Royal Prima Tbk ranks #533 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 80.3%.
Is PT Royal Prima Tbk's Days Sales Outstanding too high?
PT Royal Prima Tbk's current Days Sales Outstanding of 89.71 is near median its 10-year median of 89.70. Over the past 10 years, this metric has ranged from a low of 35.96 to a high of 111.81. The Healthcare Providers & Services industry median Days Sales Outstanding is 45.78. PT Royal Prima Tbk's value of 89.71 is 96% above this industry median. Based on the distribution chart, PT Royal Prima Tbk ranks #533 out of 664 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, PT Royal Prima Tbk has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PT Royal Prima Tbk's Days Sales Outstanding compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, PT Royal Prima Tbk ranks #533 out of 664 companies for Days Sales Outstanding. This places PT Royal Prima Tbk in the lower half of its industry. The industry median Days Sales Outstanding is 45.78. PT Royal Prima Tbk's value of 89.71 is 96% above this benchmark. Historically, PT Royal Prima Tbk's own Days Sales Outstanding has ranged from 35.96 to 111.81 over the past decade. While the company's 10-year median is 89.70 vs. the industry median of 45.78, PT Royal Prima Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Healthcare Providers & Services company?
The median Days Sales Outstanding among Healthcare Providers & Services companies is 45.78, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Royal Prima Tbk's current Days Sales Outstanding of 89.71 is 96% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on PT Royal Prima Tbk and its competitors. For the Healthcare Providers & Services industry, the median Days Sales Outstanding is 45.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Royal Prima Tbk's current Days Sales Outstanding is 89.71, which is near median its own 10-year median of 89.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Royal Prima Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Royal Prima Tbk (ISX:PRIM) is currently considered Significantly Overvalued. The stock's GF Value™ is Rp78.36, compared to a current price of Rp120.00 — trading 53.1% above its estimated fair value. The current Days Sales Outstanding is 89.71, which is near median its 10-year median of 89.70 and 96% above the Healthcare Providers & Services industry median of 45.78. PT Royal Prima Tbk's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For PT Royal Prima Tbk (ISX:PRIM), the current Days Sales Outstanding is 89.71 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Royal Prima Tbk (ISX:PRIM) Overvalued in 2026?
Based on GuruFocus' analysis, PT Royal Prima Tbk stock appears to be overvalued.
The current stock price of Rp120.00 is trading 53.1% above its estimated GF Value™ of Rp78.36.
GuruFocus considers PT Royal Prima Tbk to be Significantly Overvalued.
Key valuation signals for ISX:PRIM:
Days Sales Outstanding: 89.71 (near median its 10-year median of 89.70)
GF Value™: Rp78.36 vs. price of Rp120.00 (53.1% above fair value)
Industry Position: 96% above the Healthcare Providers & Services median (#533 of 664)
No single metric tells the full story. See the ISX:PRIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Royal Prima Tbk is engaged in health services which consist of the provision of hospital services, polyclinics, hall treatment, maternity hospital, and specialist hospital. It has three geographic segments: RSU Royal Prima, RS Royal Prima Jambi, and Rumah Sakit Marelan. The company generates the majority of its revenue from RSU Royal Prima segment. The company generates revenue from Drugs and medical supplies, doctors' and nurses' fees, Hospital facilities, Room services, and Others.
65GF Score
Get the complete analysis for ISX:PRIM
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:PRIM has been successfully added to your 
